+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer

How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer

Oncologist 19(10): 1046-1055

Gastric cancer (GC) is the second leading cause of cancer death worldwide. GC is a heterogeneous disease in terms of histology, anatomy, and epidemiology. There is also wide variability in how GC is treated in both the resectable and unresectable settings. Identification of prognostic and predictive biomarkers is critical to help direct and tailor therapy for this deadly disease. A literature search was done using Medline and MeSH terms for GC and predictive biomarkers and prognostic biomarkers. The search was limited to human subjects and the English language. There was no limit on dates. Published data and unpublished abstracts with clinical relevance were included. Many potential prognostic and predictive biomarkers have been assessed for GC, some of which are becoming practice changing. This review is focused on clinically relevant biomarkers, including EGFR, HER2, various markers of angiogenesis, proto-oncogene MET, and the mammalian target of rapamycin. GC is a deadly and heterogeneous disease for which biomarkers are beginning to change our understanding of prognosis and management. The recognition of predictive biomarkers, such as HER2 and vascular endothelial growth factor, has been an exciting development in the management of GC, validating the use of targeted drugs trastuzumab and ramucirumab. MET is another potential predictive marker that may be targeted in GC with drugs such as rilotumumab, foretinib, and crizotinib. Further identification and validation of prognostic and predictive biomarkers has the potential transform how this deadly disease is managed.

(PDF emailed within 0-6 h: $19.90)

Accession: 053595952

Download citation: RISBibTeXText

PMID: 25142842

DOI: 10.1634/theoncologist.2014-0006

Related references

Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World Journal of Gastroenterology 20(14): 3858-3874, 2015

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?. Virchows Archiv 464(3): 367-378, 2014

Synergistic role between p53 and JWA: prognostic and predictive biomarkers in gastric cancer. Plos One 7(12): E52348-E52348, 2013

Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Critical Reviews in Oncology/Hematology 96(1): 67-80, 2015

Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagnostic Molecular Pathology 22(3): 127-137, 2014

Prognostic Value of Inflammatory Biomarkers in Gastric Cancer Patients and the Construction of a Predictive Model. Digestive Surgery: 1-10, 2018

The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer 125(1): 127-134, 2018

Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. Biomed Research International 2017: 7869802-7869802, 2017

Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy. Zhonghua Zhong Liu Za Zhi 39(3): 195-200, 2017

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clinical Cancer Research 19(24): 6957-6966, 2014

Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed. Annals of Oncology, 2018

Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. Journal of Translational Medicine 13: 66-66, 2016

Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells. World Journal of Gastroenterology 24(21): 2236-2246, 2018

Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer. Tumour Biology 36(3): 2097-2103, 2015

Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Research 17: 21-21, 2015